A03DC - search results

United States - English - NLM (National Library of Medicine)

adcirca- tadalafil tablet

aphena pharma solutions - tennessee, llc - tadalafil (unii: 742sxx0ict) (tadalafil - unii:742sxx0ict) - tadalafil 20 mg - adcirca® is indicated for the treatment of pulmonary arterial hypertension (pah) (who group 1) to improve exercise ability. studies establishing effectiveness included predominately patients with nyha functional class ii – iii symptoms and etiologies of idiopathic or heritable pah (61%) or pah associated with connective tissue diseases (23%). do not use adcirca in patients who are using any form of organic nitrate, either regularly or intermittently. adcirca potentiates the hypotensive effect of nitrates. this potentiation is thought to result from the combined effects of nitrates and adcirca on the nitric oxide/cgmp pathway [see clinical pharmacology (12.2)] . do not use adcirca in patients who are using a gc stimulator, such as riociguat. adcirca may potentiate the hypotensive effects of gc stimulators. adcirca is contraindicated in patients with a known serious hypersensitivity to tadalafil (adcirca or cialis). hypersensitivity reactions have been reported, including stevens-johnson syndrome and exfoliati